CARDS: atorvastatin reduces risk of cardiovascular events in diabetes

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1446, 2004-01, pp. : 9-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes

By Ramsey Scott D.   Clarke Lauren D.  

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 329-339

Adis International

Access to resources Recommend Favorite

Atorvastatin: A Review of its Use in the Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

By Croom Katherine F.   Plosker Greg L.  

Drugs, Vol. 65, Iss. 1, 2005-01 ,pp. : 137-152

Adis International

Access to resources Recommend Favorite

Simvastatin reduces cardiovascular risk

By  

Inpharma, Vol. 1, Iss. 1346, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Atorvastatin as standard therapy on the CARDS

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events

By Plosker Greg L.   Lyseng-Williamson Katherine A.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1031-1053

Adis International

Access to resources Recommend Favorite